Whole exomes sequencing for neurofibromatosis type I patients complicated with gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. 85% GISTs carry mutations in the KIT or PDGFRA and the rest 15% cases which present without KIT or PDGFRA mutation are called wild type (WT) GISTs. Patients with neurofibromatosis type I (NF1) have higher risk of developing GISTs and all the cases belong to the WT GISTs. Compared with the somatic cases, NF1-associated GISTs are characterized with unique clinical manifestations and are not responding to Imatinib-the first line drug for GISTs. This study was designed to identify the central somatic mutations in NF1-associated GISTs by conducting whole exomes sequencing (WES). We sequenced the tumor and peripheral blood exomes of two patients who developed KIT/PDGFRA wild-type GISTs concurrent with NF1. Three novel somatic mutated genes (PRSS and FOLR3, and TAS2R43) were identified in GISTs but not NF1 tumors. And we further test the function of the mutated genes (PRSS3, FOLR3) in GIST cells and prove the oncogenic roles they play in NF-1 associated GIST. This is the first report, to our knowledge, that WES is applied to study the genomic profile of tumors and peripheral blood exomes in NF1 patients. And it is also the first time that PRSS3 and FOLR3 are revealed to be associated with the development of NF1-associated GISTs.

[1]  D. Radisky,et al.  Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy. , 2016, The Biochemical journal.

[2]  Yingyong Hou,et al.  Successful establishment of patient-derived tumor xenografts from gastrointestinal stromal tumor-a single center experience. , 2016, American journal of cancer research.

[3]  M. Mohammadi,et al.  Retraction Note to: Clinical significance and expression of the PRSS3 and Wiskott–Aldrich syndrome protein family verprolin-homologous protein 1 for the early detection of epithelial ovarian cancer , 2016, Tumor Biology.

[4]  Yingyong Hou,et al.  A novel germline mutation in SDHA identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma. , 2015, International journal of clinical and experimental pathology.

[5]  E. Wardelmann,et al.  Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy , 2015, Expert review of anticancer therapy.

[6]  Hong-yan Cheng,et al.  PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer. , 2015, Gynecologic oncology.

[7]  M. Saif,et al.  Neurofibromatosis type 1 and GIST: is there a correlation? , 2014, Anticancer research.

[8]  J. Sanderson,et al.  Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations , 2014, The Pharmacogenomics Journal.

[9]  I. Shih,et al.  Gene expression signatures of primary and metastatic uterine leiomyosarcoma. , 2014, Human pathology.

[10]  G. Drouin,et al.  Purifying selection against gene conversions in the folate receptor genes of primates. , 2014, Genomics.

[11]  D. Radisky,et al.  PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer , 2012, Molecular Cancer Research.

[12]  A. Agaimy,et al.  Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations. , 2012, International journal of clinical and experimental pathology.

[13]  A. D. Van den Abbeele,et al.  Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib , 2009, Pediatric blood & cancer.

[14]  T. de Ravel,et al.  Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. , 2009, The Lancet. Oncology.

[15]  C. Mussi,et al.  Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1 , 2008, Clinical Cancer Research.

[16]  Narasimhan P. Agaram,et al.  Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors , 2008, Clinical Cancer Research.

[17]  R. Ferner.  Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective , 2007, The Lancet Neurology.

[18]  D. Evans,et al.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 , 2006, Journal of Medical Genetics.

[19]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[20]  F. Speleman,et al.  Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. , 2006, Human molecular genetics.

[21]  H. Joensuu,et al.  NF1-Associated Gastrointestinal Stromal Tumors Have Unique Clinical, Phenotypic, and Genotypic Characteristics , 2005, The American journal of surgical pathology.

[22]  J M Friedman,et al.  NF1 gene and neurofibromatosis 1. , 2000, American journal of epidemiology.

[23]  N. Muja,et al.  Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with Type 1 Neurofibromatosis , 1998, Oncogene.

[24]  S. Rothenberg,et al.  Characterization of the gene encoding a folate-binding protein expressed in human placenta. Identification of promoter activity in a G-rich SP1 site linked with the tandemly repeated GGAAG motif for the ets encoded GA-binding protein. , 1994, The Journal of biological chemistry.

[25]  R. B. Johnson,et al.  Gastrointestinal neoplasms in von Recklinghausen's disease. , 1969, Southern medical journal.

[26]  T. D. Ghrist.  GASTROINTESTINAL INVOLVEMENT IN NEUROFIBROMATOSIS. , 1963, Archives of internal medicine.